UNSPSC 51392607: Metaraminol tartrate

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZC4202M9P3, chemically known as benzyl alcohol, alpha-(1-aminoethyl)-m-hydroxy-, (-)- but more generally known as metaraminol bitartrate, which bears US NIH Compound Identifier 5906. European Medicines Agency schedules Metaraminol bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03194MIG.

Most nations, for tariff and trade purposes, schedule metaraminol tartrate under HS 29399900 and SITC 54149. SMILES: C[C@@H]([C@@H](C1CCCC(C1)O)O)N.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51392607 Metaraminol tartrate is a Commodity code that nominally identifies a single pharmaceutical product, but recent state and local opportunities tagged under this code show minimal alignment with its abstract scope. The Seminole County, Florida IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) procures emergency medical supplies rather than metaraminol tartrate specifically. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026) addresses pharmacy benefit strategy and vendor capabilities for prescription fulfillment channels, not a single active pharmaceutical ingredient. State and local buyers tagged to this code appear to be county health departments and state health agencies, but the recent opportunities do not reflect procurement activity for metaraminol tartrate itself—they reflect broader pharmaceutical procurement, emergency medical supply sourcing, and pharmacy program design.

The code shows little relevant recent activity aligned with its nominal pharmaceutical product scope. Geographic activity visible in the opportunities spans Florida and Texas, but both records represent divergent procurement functions (emergency supply contracting and pharmacy benefit program design) rather than consolidated demand for metaraminol tartrate as a line item. Vendors evaluating pursuit under this code should note the mismatch between the code's product-specific designation and the state and local work actually being tagged to it, and should verify through direct issuing-body inquiry whether metaraminol tartrate procurement opportunities exist in their target markets before dedicating business development resources to this code.